Skip to content

Large-scale study validates simple blood test for dementia.

Scientists at Rigshopitalet, Herlev Hospital and the University of Copenhagen identify a new biomarker that can predict the risk of developing dementia by way of a simple blood test. In the long term, this could mean better prevention and thus at least postponement of the illness and at best evading the development all together. The study is published in the journal, Annals of Neurology.

As opposed to cardiovascular diseases, where the level of cholesterol in the blood indicates the risk of cardiac arrest, there are no such trustworthy markers in human blood in terms of diagnosing the risk of dementia setting in. However, the researchers have now identified a new biomarker, measurable in a simple blood test, which will help predict the onset of dementia.

The blood test will help provide a more precise risk evaluation of a person’s risk of developing dementia later in life. Thus the people at the greatest risk of developing the illness are more easily identified than at present.  Researchers hope that with time, this new blood test will be applicable in clinical practice.  The team state that the blood test will enable an earlier and more focused prevention effort, thus prolonging the onset of the illness and raising the individual’s quality of life.

Globally, in excess of 35 million people suffer dementia, in Denmark alone, there are approx. 80,000 who suffer this illness. Prevalence increases in step with aging, and as people’s life years are continually on the rise in most countries, there is also an increasing need to be able to identify the people who are at the greatest risk of suffering dementia.

In the study, researchers show that a low level of the biomarker apolipoprotein E in the blood, increases the risk of developing dementia in the future. This was revealed in comprehensive studies of the general public, the Herlev-Oesterbro Study and the Oesterbro Study, involving 76,000 people.

The healthy brain consists of millions of interconnected nerve cells. The brain in a person suffering dementia is very different. The well-organised, structured coordination of nerve cells is intersected by, among other things, senile plaques that consist of the viscous compound, β-amyloid.

In the current study the low level of apolipoprotein E in the blood most likely reflects a low level of apolipoprotein E in the brain, and this indicates that the viscous compound, β-amyloid, is less effectively removed. Thus the study’s results underpin a biological mechanism.

The researchers explain that over time, this increased biological knowledge about dementia can constitute a point of departure for the development of new drugs.

Source:  University of Copenhagen

Credit:  CSIRO and the Walter and Eliza Hall Institute of Medical Research (WEHI) 2015.
Credit: CSIRO and the Walter and Eliza Hall Institute of Medical Research (WEHI) 2015.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

6 thoughts on “Large-scale study validates simple blood test for dementia. Leave a comment

  1. Thank you for notifying resent research regarding a simple way to denote dementia. You state :In the current study the low level of apolipoprotein E in the blood most likely reflects a low level of apolipoprotein E in the brain…” Since this AOPE is a gene, is there any way known to synthesize this gene or perhaps chemicals/herbs/natural products to consume to stimulate production of APOE? Thank you.

  2. Low levels of ApoE may also reflect retention in brain, and hence higher levels of brain ApoE. The E3 variant of this protein is known to bind to oligomers of Abeta with nM affinity, and is a well established risk factor in Alzheimer’s disease.

  3. I wonder about what is known about the relationship between blood levels of ApoE and brain levels of same –blood levels could reflect brain levels or retention of ApoE levels in the brain. There is some precedent for the phenomenon –e.g., the early reports of B-endorphin increases in blood as evidence off the opioid’s responsibility for the “runner’s high “, had to later be tempered somewhat as the magnitude of post run B-endorphin in CSF was much less (than in blood) –just a thought.

Leave a Reply

Translate »